[1] Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients. Retrieved November 29, 2024, from https://immixbio.com/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-of-hematology-ash-annual-meeting-in-16-relapsed-refractory-al-amyloidosis-patients/

[2] IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting. Retrieved November 29, 2024, from https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-continued-durable-remissions-phase-1-trial-inb

[3] S.BIOMEDICS Investigational Cell Therapy for Parkinson’s Disease With TED-A9 Shows Positive Data at 12-months in Phase 1/2a Clinical Trial. Retrieved November 29, 2024, from https://www.businesswire.com/news/home/20241126606645/en/S.BIOMEDICS-Investigational-Cell-Therapy-for-Parkinson%E2%80%99s-Disease-With-TED-A9-Shows-Positive-Data-at-12-months-in-Phase-12a-Clinical-Trial

[4] SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/scg-cell-therapy-presents-promising-phase-1-data-for-a-novel-hbv-specific-tcr-t-therapy-scg101-at-the-aasld-liver-meeting-2024-302314896.html

[5] Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference. Retrieved November 29, 2024, from https://www.globenewswire.com/news-release/2024/11/25/2986577/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-SNO-Annual-Conference.html

[6] 2876 ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Retrieved November 29, 2024, from https://ash.confex.com/ash/2024/webprogram/Paper193493.html

[7] HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-announce-successful-completion-of-a-first-in-human-study-for-potential-disease-modifying-therapy-for-parkinsons-disease-302315158.html

[8] MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS). Retrieved November 29, 2024, from https://www.businesswire.com/news/home/20241125058999/en/MaaT-Pharma-Announces-Positive-Phase-1b-Results-Meeting-Primary-Endpoint-in-the-Evaluation-of-MaaT033-in-Amyotrophic-Lateral-Sclerosis-ALS/

[9] Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial. Retrieved November 29, 2024, from https://www.accesswire.com/945940/hemogenyx-pharmaceuticals-plc-announces-irb-approval-for-phase-i-clinical-trial

[10] GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/gc-biopharma-and-novel-pharma-first-patient-dosed-in-global-phase-i-clinical-trial-for-mps-iiia-treatment-302315952.html

[11] Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/avirmax-biopharma-announces-first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv-302313714.html

[12] uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy. Retrieved November 29, 2024, from https://www.globenewswire.com/news-release/2024/11/21/2985098/0/en/uniQure-Announces-Dosing-of-First-Patient-in-GenTLE-Phase-I-IIa-Clinical-Trial-of-AMT-260-for-the-Treatment-of-Refractory-Mesial-Temporal-Lobe-Epilepsy.html

[13] Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. Retrieved November 29, 2024, from https://investors.tenayatherapeutics.com/news-releases/news-release-details/tenaya-therapeutics-doses-first-patient-ridgetm-1-phase-1b

[14] Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial. Retrieved November 29, 2024, from https://www.accesswire.com/945940/hemogenyx-pharmaceuticals-plc-announces-irb-approval-for-phase-i-clinical-trial